Celgene has appointed Michael Zaiac as vice president, medical affairs for its EMEA haematology-oncology business.
Zaiac joins the company’s Switzerland-based international business from GlaxoSmithKline, where he was most recently franchise medical head for its immuno-inflammation and infectious diseases operations.
Prior to joining the pharmaceutical industry Zaiac served for several years as senior house officer in the UK in general, orthopaedic and cardiothoracic surgery, as well as working in Germany in general and vascular surgery and surgical oncology.
Marie-France Tschudin, corporate vice president of haematology-oncology at Celgene International, said “I am really pleased to have Michael on board to head up our haematology-oncology medical affairs team.
“This is a really exciting time for Celgene in EMEA, with three European approvals already in 2015, two of which are in haematology-oncology. His expertise in this area will give us the strong support we need at this fast-moving time.”